Clinical Trial Update: Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Grazoprevir/Elbasvir to Sofosbuvir+Pegylated Interferon+Ribavirin in Hepatitis C virus genotypes 1, 4, or 6; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Grazoprevir / Elbasvir (MK-5172/MK-8742) (Grazoprevir and Elbasvir)
• Sofosbuvir + Pegylated Interferon + Ribavirin

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2017-01-11